Comparison of patients with myeloma receiving zoledronic acid vs denosumab: a nationwide retrospective cohort study
Blood Adv
.
2024 Nov 12;8(21):5539-5541.
doi: 10.1182/bloodadvances.2024013600.
Authors
Ghulam Rehman Mohyuddin
1
,
Jenny S Guadamuz
2
3
,
Mustafa S Ascha
2
,
Brian C-H Chiu
4
,
Pritesh R Patel
5
,
Karen Sweiss
6
,
Rebecca Rohrer
2
,
Douglas Sborov
1
,
Gregory S Calip
2
7
Affiliations
1
Division of Hematology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.
2
Flatiron Health, New York, NY.
3
Program on Medicines and Public Health, School of Pharmacy, University of Southern California, Los Angeles, CA.
4
Department of Public Health Sciences, The University of Chicago, Chicago, IL.
5
Division of Hematology and Oncology, University of Illinois at Chicago, Chicago, IL.
6
Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, IL.
7
Department of Pharmacy Systems, Outcomes and Policy, University of Illinois at Chicago, Chicago, IL.
PMID:
39207867
DOI:
10.1182/bloodadvances.2024013600
No abstract available